Charles River Labs Q4 2023 Results: Revenue Decline and Earnings Miss

Details

announced its Q4 2023 results, reporting a 7.9% decline in revenue to $1.01 billion and a 0.8% decrease in diluted EPS to $3.62 on a GAAP basis. The company also provided guidance for 2024, anticipating modest revenue growth and earnings per share between $7.90 and $8.40 for GAAP EPS and $10.90 and $11.40 for non-GAAP EPS.

Items reported

Exhibits (1)

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.